Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7049665 for prevention of relapse during corticosteroid tapering in autoimmune hepatitis
NL-OMON51170Phase 2Active, not recruiting
- Sponsor
- Covance
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of melredableukin alfa in autoimmune hepatitis (AIH) (3 arms), sponsored by Covance. Primary endpoint: Time to relapse from randomization. Started Apr 2021; status: active, not recruiting.
02
Drugs
melredableukin alfa
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NL-OMON51170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51170.